Piet Hinoul MD, PhD 

CHIEF MEDICAL OFFICER

A global healthcare executive, Piet Hinoul, M.D., Ph.D., brings 30 years of healthcare experience to Virtual Incision, of which the past 15 have been spent in the medtech industry. In his past roles, Piet has served as Senior V.P., Global Head Medical Affairs at Novocure, and V.P., Global Head for Medical, Clinical, and Pre-Clinical Affairs for the surgical subsidiary of Johnson & Johnson, Ethicon. Piet is a European Board-certified gynecologist whose work has been published extensively on various surgery topics and who has lectured internationally throughout his career on the fields of urogynecology, surgery, and medical device innovation. Piet earned his M.D. from the University of Leuven, and his Ph.D. in biomedical sciences from the University of Amsterdam.

Disclosure and Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. Patients and doctors should review all available information on nonsurgical and surgical options and associated risks in order to make an informed decision.

Serious complications may occur in any surgery, including minimally invasive surgery with the MIRA Surgical System, up to and including death. Serious risks include, but are not limited to, injury to tissues and organs, and/or conversion to other surgical techniques which could result in a longer operative time and/or complications.

For important safety information, including surgical risks and considerations, please also refer to www.virtualincision.com/safety-information. For the product’s indications for use, risks, full cautions, and warnings, please refer to the associated user manual(s).

Individual outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics, surgeon, and/or hospital experience.

MIRA Surgical System Precaution Statement

The demonstration of safety and effectiveness for the representative specific procedures was based on evaluation of the MIRA Surgical System as a surgical device and did not include evaluation of outcomes related to the treatment of cancer (overall survival, disease-free survival, local recurrence) or treatment of the patient’s underlying disease/condition. Device usage in all surgical procedures should be guided by the clinical judgment of an adequately trained surgeon.

Contact

Sign up today to be the first to get Virtual Incision news and updates

SIGN UP
Back to Top